Dong-A Pharmaceutical Co., Ltd.
KKRX:00064089,800.00
KRW
-900.00
(-0.99%)
ISIN
KR7000640003
Return %
Stock
S&P 500
1Y
-15.53
14.39
3Y
0.18
81.42
5Y
-12.60
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Min-Young Kim
- Full Time Employees
- 82
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 64, Cheonho-daero Seoul SL South Korea 02587
- IPO Date
- Feb 10, 1970
- Website
- donga.co.kr
- Similar Companies
- Business
- Dong-A Socio Holdings Co., Ltd. is a South Korean holding company primarily engaged in the pharmaceutical industry, operating through multiple subsidiaries. Its core products and services include over-the-counter drugs and quasi-drugs; biosimilars and consignment medicines; prescription drugs; medical devices and equipment; health functional foods and consumer healthcare products notably including the Bacchus energy drink; cosmetics; logistics and fulfillment services; packaging solutions such as glass and PET bottles, aluminum and plastic caps, and paper packaging boxes; and beverages including mineral and carbonated water and mixed drinks. The company also has operations in contract development and manufacturing organization (CDMO) services for biosimilar and pharmaceutical products, oligonucleotide therapeutics, digital healthcare devices, and various construction and real estate services. It serves markets primarily in South Korea with some international presence through subsidiaries like Dong-A Chammed, a manufacturer of medical equipment with a distribution footprint in over 70 countries worldwide. Founded in 1932, the company is headquartered in Seoul, South Korea. Recent major company developments include strategic expansions in biosimilar and novel therapeutics through its subsidiaries such as Dong-A ST, which focuses on research and development of ethical drugs including biological anti-tumor agents and immune disease therapeutics. Dong-A Socio Holdings has also advanced in its contract development manufacturing capabilities with STgen Bio, enhancing production of novel modalities including cell and gene therapies. Additionally, the company has pursued innovation in medical solutions through partnerships, including collaborative agreements with biotech firms for expansion in digital healthcare and advanced drug development. Dong-A Chammed continues to expand its global footprint in medical devices. These operational expansions reflect a strategic focus on broadening the pharmaceutical and healthcare portfolio while maintaining stable consumer products and strengthening logistics and packaging segments. The company's diversified structure differentiates it within the Korean pharmaceutical sector, comprising three main pillars: Dong-A Pharmaceutical, which leads in consumer healthcare and OTC products; Dong-A ST, its listed pharmaceutical R&D subsidiary; and Yongma Logis, a logistics and distribution arm. This diversified business spans pharmaceuticals, medical devices, consumer wellness, biosimilars, logistics, packaging, and other services, positioning Dong-A Socio Holdings as a comprehensive healthcare and related service provider with a robust presence in the domestic market and growing international scope. Overall, Dong-A Socio Holdings is a long-established South Korean holding firm with a broad portfolio encompassing pharmaceuticals, consumer healthcare, manufacturing, logistics, and packaging solutions, underpinned by recent strategic alliances, acquisitions, and advancements in biosimilars and novel therapeutics to drive future growth. It is headquartered in Seoul and was founded in 1932.